Sofwave Medical Ltd. SOFW
TASE · Israel · Health Technology
ILA 3,340.00-206.00 (-5.81%)
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a growing medical aesthetic market, with the market for non-invasive/minimally invasive procedures valued at RMB 146.0 billion (approximately US$20.6 billion) in 20231 SAN CLEMENTE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthe
SAN CLEMENTE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026. About Sofwave MedicalSofwave Medical Ltd. (TASE: SOFW) is a global
A prospective randomized controlled trial of an aesthetic EMS platform to assess objective functional performance reports improvements across four standardized testsSAN CLEMENTE, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced the publication of data from a new randomized controlled clinical study of the Company’s proprietary PlyoPulse™ technology, titled “
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.